Ozempic could be the next target of Medicare drug price negotiations – here’s why

Wall Street analysts expect Ozempic to be selected for price negotiations in 2025 due to the amount of money Medicare Part D already spends on the drug.

Previous post Currencies: The U.S. dollar strikes back: What’s next after August rally
Next post : Goldman Sachs fintech unit TxB gets compliance warning from Fed: report